Scarica l'app Stockscreener
8.50
8.31%
-0.77
Dopo l'orario di chiusura:
8.50
Alvotech Borsa (ALVO) Ultime notizie
Alvotech (NASDAQ:ALVO) Stock Price Down 3.5%Here's Why - MarketBeat
Alvotech stock hits 52-week low at $8.88 amid market challenges - Investing.com
Alvotech (NASDAQ:ALVO) Hits New 1-Year LowHere's Why - MarketBeat
The Escalator: HHS, Spectrum Science, Alvotech and more - Medical Marketing and Media
Oaktree Capital Management LP Sells 606,322 Shares of Alvotech (NASDAQ:ALVO) - MarketBeat
Who’s Hired? Alvotech Appoints Strategy And Quality Chiefs - insights.citeline.com
Biosimilars Help Alvotech Revenues Soar Over 400% Year Over Year - Center for Biosimilars®
Alvotech (NASDAQ:ALVO) Stock Price Down 7.6%Time to Sell? - MarketBeat
Alvotech (NASDAQ:ALVO) Issues Earnings Results - MarketBeat
Alvotech (NASDAQ:ALVO) Just Reported And Analysts Have Been Lifting Their Price Targets - Yahoo Finance
Earnings call transcript: Alvotech’s Q4 2024 results show revenue surge By Investing.com - Investing.com Australia
Aurion names Arnaud Lacoste CEO - BioCentury
Alvotech Reveals Ramp-Up In Development As Sales Explode In 2024 - insights.citeline.com
Alvotech Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - simplywall.st
Alvotech Achieves Record Revenue Growth in 2024 - TipRanks
Earnings call transcript: Alvotech’s Q4 2024 results show revenue surge - Investing.com India
Trump Must Be ‘Harsh’ With Big Pharma, Says Icelandic Drugmaker - Bloomberg
Alvotech Appoints Dr. Balaji V. Prasad As Chief Strategy Officer - MarketScreener
Alvotech Appoints New Chief Strategy Officer to Strengthen Market Position - TipRanks
Alvotech Achieves Record 2024 Financial Results and Expands Biosimilar Pipeline - TipRanks
Iceland's Alvotech Appoints Chief Strategy Officer - MarketScreener
Alvotech Appoints Dr. Balaji V. Prasad as Chief Strategy Officer - The Manila Times
Alvotech Strengthens Leadership: Wall Street Veteran with Medical Background Takes Strategic Helm - Stock Titan
Alvotech earnings missed by $0.04, revenue topped estimates - Investing.com Australia
Alvotech SA reports results for the quarter ended December 31Earnings Summary - TradingView
Alvotech earnings missed by $0.04, revenue topped estimates By Investing.com - Investing.com South Africa
Alvotech : Press Release Full Year 2024 - MarketScreener
Alvotech Reports Record Results for 2024 and Provides Business Update - The Manila Times
Deal Watch: Eyenovia Looks At New Direction In Proposed Merger With Betaliq - insights.citeline.com
Alvotech And Advanz Make First Omalizumab Filing - Citeline News & Insights
Alvotech SA MHRA Accepts Marketing Application For AVT23 Biosimilar To Xolair - Marketscreener.com
Alvotech’s Biosimilar to Xolair Gains UK Regulatory Acceptance - TipRanks
Alvotech , Kashiv Biosciences LLC and Advanz Pharma Announces UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair - MarketScreener
UK Medicines and Healthcare Products Regulatory - GlobeNewswire
UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab) - The Manila Times
Earnings Scheduled For March 26, 2025 - Benzinga
UK Medicines and Healthcare Products Regulatory Agency - GlobeNewswire
UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab) - GlobeNewswire Inc.
Royce & Associates LP Raises Stock Holdings in Alvotech (NASDAQ:ALVO) - MarketBeat
Alvotech, Partners Say UK Regulator Accepted Market Application for Proposed Xolair Biosimilar - Marketscreener.com
FDA accepts Teva, Alvotech BLAs for Simponi biosimilars - MSN
Alvotech (ALVO) Expected to Announce Earnings on Wednesday - MarketBeat
Short Interest in Alvotech (NASDAQ:ALVO) Expands By 21.7% - MarketBeat
Alvotech acquires Xbrane’s R&D operations in Sweden and biosimilar candidate XB003 - MSN
FDA accepts BLA submission from Dr. Reddy's, Alvotech for proposed Prolia, Xgeva biosimilars - Drug Store News
Northland reiterates Alvotech stock with $28 target on acquisition By Investing.com - Investing.com Canada
Alvotech Acquires Xbrane's R&D Operations, Expanding Biosimilars Development Capabilities - Nasdaq
5.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):